Brought to you by 
Abeona licenses UNC-Chapel Hill's AIM AAV gene therapy for Batten disease
13 Aug 2018
Executive Summary
Abeona Therapeutics Inc. licensed exclusive worldwide rights to the University of North Carolina at Chapel Hill's AIM adeno-associated virus (AAV) gene therapy vector platform, which targets the central nervous system, and an associated gene therapy ABO202 (AAV-CLN1) for infantile neuronal ceroid lipofuscinosis, also known as juvenile Batten disease (JBD).
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
-
Drug Delivery
- Controlled Release
- Macromolecule
-
Drug Delivery
-
Biotechnology
- Gene Therapy, Cell Therapy
- Large Molecule
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Abeona licenses UNC-Chapel Hill's AIM AAV gene therapy for Batten disease
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice